Cargando…

Hyperprogressive Disease After Immunotherapy: A Case Report of Pulmonary Enteric Adenocarcinoma

Primary pulmonary enteric adenocarcinoma (PEAC) is a rare invasive adenocarcinoma clinically similar to metastatic colorectal adenocarcinoma (MCRC). Although many studies have addressed the differential diagnosis of PEAC, few have described the treatment of PEAC, especially using immunotherapy. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Chun-Hong, Shi, Shenghao, Dong, Wen, Xiao, Lizhi, Zang, Hongjing, Wu, Fang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8937032/ https://www.ncbi.nlm.nih.gov/pubmed/35321429 http://dx.doi.org/10.3389/fonc.2022.799549

Ejemplares similares

Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
por: Zang, Hongjing, et al.
Publicado: (2020)

Hyperprogression after immunotherapy
por: Abbas, Waseem, et al.
Publicado: (2019)

Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab
por: Sama, Shashank, et al.
Publicado: (2019)

Hyperprogression After Immunotherapy for Primary Small Cell Neuroendocrine Carcinoma of the Ureter: A Case Report
por: Qing, Defeng, et al.
Publicado: (2021)

Hyperprogression under Immunotherapy
por: Frelaut, Maxime, et al.
Publicado: (2019)

Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics
por: Singla, Rishu, et al.
Publicado: (2021)

Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
por: Ji, Zhi, et al.
Publicado: (2019)

Hyperprogression: A novel response pattern under immunotherapy
por: Han, Xue‐jiao, et al.
Publicado: (2020)

Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench
por: Subbiah, Vivek, et al.
Publicado: (2022)

Is hyperprogressive disease a specific phenomenom of immunotherapy?
por: Brambilla, Marta, et al.
Publicado: (2020)

Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
por: Adashek, Jacob J., et al.
Publicado: (2020)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
por: Shen, Pan, et al.
Publicado: (2021)

Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report
por: Varnier, Romain, et al.
Publicado: (2021)

Exploration of the immunogenetic landscape of hyperprogressive disease after combined immunotherapy in cancer patients
por: Gong, Caifeng, et al.
Publicado: (2023)

Hyperprogressive disease after avelumab maintenance therapy in a patient with advanced ureter cancer: A case report
por: Ogasawara, Keita, et al.
Publicado: (2022)

Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer
por: Wang, Zhenghang, et al.
Publicado: (2021)

Hyperprogression of Liver Metastasis With Neoadjuvant Immunotherapy for Soft Tissue Sarcoma
por: Chan, Abigail S, et al.
Publicado: (2020)

Hyperprogressive disease after treatment with pembrolizumab in lung adenocarcinoma: An autopsy case study
por: Tanaka, Yuko, et al.
Publicado: (2019)

A pulmonary enteric adenocarcinoma patient harboring a rare EGFR exon 19 P753S mutation: Case report and review
por: Xu, Xiaohu, et al.
Publicado: (2022)

Extremely high infiltration of CD8(+)PD-L1(+) cells detected in a stage III non-small cell lung cancer patient exhibiting hyperprogression during anti-PD-L1 immunotherapy after chemoradiation: A case report
por: Wu, Changshun, et al.
Publicado: (2022)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
por: Gabryś, H. S., et al.
Publicado: (2022)

Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer
por: Xiong, Donghai, et al.
Publicado: (2018)

Clinical features and prognosis of pulmonary enteric adenocarcinoma: A retrospective study in China and the SEER database
por: Wang, Qike, et al.
Publicado: (2023)

Hyperprogression: A Unique Phenomenon of Progression of Existing Tumor Secondary to Immunotherapy
por: Mandal, Shobha, et al.
Publicado: (2021)

Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
por: Wei, Zhanqi, et al.
Publicado: (2022)

Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?
por: Britt, Alec S., et al.
Publicado: (2022)

Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study
por: Zou, Siyi, et al.
Publicado: (2022)

Hyperprogression under immunotherapy: a new form of immunotherapy response?—a narrative literature review
por: Lin, Miaozhen, et al.
Publicado: (2021)

Genomic alterations associated with pseudoprogression and hyperprogressive disease during anti-PD1 treatment for advanced non-small-cell lung cancer
por: Zhou, Rui, et al.
Publicado: (2023)

Pulmonary enteric adenocarcinoma
por: Gong, Jiali, et al.
Publicado: (2021)

Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis
por: Zhao, Zijun, et al.
Publicado: (2022)

Enteral lorlatinib after immune hyperprogression as a treatment option for anaplastic lymphoma kinase‑positive non‑small cell lung cancer: A case report
por: Wang, Huan, et al.
Publicado: (2023)

Iodine-125 radioactive particles antagonize hyperprogressive disease following immunotherapy: A case report
por: Yang, Ning, et al.
Publicado: (2020)

Hyperprogression of cutaneous T cell lymphoma after anti–PD-1 treatment
por: Gao, Yumei, et al.
Publicado: (2023)

Case Report: Tumor Microenvironment Characteristics in a Patient With HER2 Mutant Lung Squamous Cell Carcinoma Harboring High PD-L1 Expression Who Presented Hyperprogressive Disease
por: Xia, Lixia, et al.
Publicado: (2021)

Immunotherapy and Targeting the Tumor Microenvironment: Current Place and New Insights in Primary Pulmonary NUT Carcinoma
por: Li, Xiang, et al.
Publicado: (2021)

Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy
por: Okeya, Komugi, et al.
Publicado: (2019)

JAG1 is correlated to suppressive immune microenvironment and predicts immunotherapy resistance in lung adenocarcinoma
por: He, Jing, et al.
Publicado: (2023)

Cuproptosis-related signature predicts prognosis, immunotherapy efficacy, and chemotherapy sensitivity in lung adenocarcinoma
por: Wu, Gujie, et al.
Publicado: (2023)

Hyperprogression of a spindle‐cell squamous carcinoma of the esophagus after esophagectomy
por: Ji, Yanli, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b14alhkqood2id5hg3ls5089e0